This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why IMab Sponsored ADR (IMAB) is Poised for a Turnaround After Losing 26.8% in 4 Weeks
by Zacks Equity Research
IMab Sponsored ADR (IMAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
I-Mab (IMAB) Down After Partner AbbVie Revises Partnership Deal
by Zacks Equity Research
I-Mab's (IMAB) partner AbbVie decides to stop early-stage development of an anti-CD47 antibody therapy targeting multiple cancer indications. IMAB intends to support the candidate's development.
I-Mab (IMAB) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
I-Mab (IMAB) recently saw a Hammer Chart Pattern which can signal that the stock is nearing a bottom.
Reata (RETA) Plunges on FDA Concerns for Kidney Failure Drug
by Zacks Equity Research
The FDA raises concerns related to data in Reata's (RETA) NDA seeking approval for bardoxolone for treating Alport syndrome. An advisory committee meeting is scheduled tomorrow.
Amryt (AMYT) Skin Disorder NDA Review Gets 3 Months Extension
by Zacks Equity Research
Amryt (AMYT) is seeking approval for Oleogel-S10 for treating epidermolysis bullosa, a rare genetic skin disorder, in the United States and Europe. The FDA extends the review period for the drug's NDA to reviewnew data submission.
Does IMab Sponsored ADR (IMAB) Have the Potential to Rally 31% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for IMab Sponsored ADR (IMAB) points to a 31.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Ascendis (ASND) Gets Positive CHMP Opinion for GHD Drug Filing
by Zacks Equity Research
Ascendis Pharma (ASND) is seeking approval for TransCon hGH for the treatment of pediatric growth hormone deficiency in Europe.
3 Small Biotech Stocks in Focus on World Arthritis Day
by Indrajit Bandyopadhyay
Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.
AbbVie (ABBV) to Co-Develop Regenxbio Eye Disease Gene Therapy
by Zacks Equity Research
AbbVie (ABBV) is set to co-develop Regenexbio's investigational gene therapy for chronic retinal diseases like wet age-related macular degeneration.
Ascendis (ASND) Rallies on First FDA-Approved Drug Skytrofa
by Zacks Equity Research
Ascendis' (ASND) Skytrofa gets FDA approval for treating growth failure in pediatric patients. The drug is also the first FDA-approved product in the company's portfolio.
Ascendis' (ASND) BLA for GHD Candidate Gets Review Extension
by Zacks Equity Research
Ascendis (ASND) is seeking approval for lonapegsomatropin as a potential treatment of pediatric growth hormone deficiency.
I-Mab (IMAB) Surges: Stock Moves 5.5% Higher
by Zacks Equity Research
I-Mab (IMAB) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Company News for Sep 8, 2020
by Zacks Equity Research
Companies in the news are: IMAB, LMPX, DPW, ANPC
AbbVie Partners With Chinese Biotech for Cancer Candidate
by Zacks Equity Research
AbbVie (ABBV) signs a collaboration agreement with China's I-Mab for developing/commercializing the latter's lemzoparlimab to address various cancer types.